Wireless Medicine Gets $45M Booster Shot, Arena’s Weight-Loss Trial Underwhelms Wall Street, Venter’s Synthetic Genomics About to Ramp Up, & Other San Diego BizTech News

We saw first-hand the increasing convergence of advanced information technologies and the life sciences here in San Diego last week. The trend was evident in the formation of a new institute for wireless healthcare, and in a roundtable discussion about personal medicine at UC San Diego that highlighted the need for easy access to electronic health records. Those stories, and the rest of the region’s BizTech news, below.

San Diego is now the home of a new medical research institute that specializes in using wireless sensors and technologies to advance health care. With $45 million in funding from the Gary and Mary West Foundation announced last week, the West Wireless Health Institute will test the use of wireless devices in clinical research to help prevent, diagnose, monitor, and treat conditions ranging from Alzheimer’s to heart disease and obesity.

San Diego’s Arena Pharmaceuticals (NASDAQ: [[ticker:ARNA]]) said a late-stage clinical trial of its drug lorcaserin met a key criteria for weight loss drug candidates set by the U.S. Food and Drug Administration. But investors were underwhelmed by the results, which showed that patients on the drug lost only about 3.6 percent more body weight than patients on a placebo. Arena still has two more clinical trials to complete, however, before seeking FDA approval.

Human Genome pioneer J. Craig Venter told scores of venture investors that Synthetic Genomics, the San Diego startup he co-founded, has engineered a species of microbes to “eat” coal and produce methane gas. With interest rising in San Diego’s emerging cleantech cluster, Venter said he’s close to making an announcement about demonstrating the technology on a larger scale.

The U.S. Department of Health and Human Services sponsored a roundtable discussion about personalized health care at UC San Diego as a way to map future funding and research priorities through 2020. But that future could arrive sooner, as the federal government plans to spend more than $19 billion on electronic health records.

Genoptix (NASDAQ: [[ticker;GXDX]]) founder and CEO Tina Nova told Luke her company has become profitable by filling a gap among laboratory testing services. Genoptix operates a specialized facility that provides a comprehensive package of diagnostic tests for cancers of the blood.

Technology developed under a Pentagon program enabled San Diego’s Avaak to develop a commercial product for home or business monitoring that will be released

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.